The first diagnostic test to classify cancers by differences in microRNAs–small pieces of RNA that regulate genes–will soon be on the market. The test distinguishes two types of lung cancer and should help doctors tailor treatments to their patients’ needs. Scientists say that tests based on microRNA profiles could prove more sensitive and reliable than existing methods, whose accuracy depends heavily on the judgment of the people analyzing them.
Product: MicroRNA test for lung cancer
Cost: Comparable to that of other molecular tests for cancer, which are priced at around $3,000 to $3,500
Company: Rosetta Genomics
Other products in this section:
The AI revolution is here. Will you lead or follow?
Join us at EmTech Digital 2019.
A stretchy stick-on patch can take blood pressure readings from deep inside your body
The flexible stamp can collect data that usually requires bulky, invasive equipment.
Clearing out old cells might help the brain
A popular anti-aging strategy keeps mice from getting senile.
“Hundreds” of crimes will soon be solved using DNA databases, genealogist predicts
CeCe Moore’s company has been helping police departments solve cold cases by uploading crime-scene DNA to public genealogy databases.